Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA.4 and BA.5 in England

Freja C. M. Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2022.08.31.22279444
Freja C. M. Kirsebom
1UK Health Security Agency, London, United Kingdom
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Andrews
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Stowe
1UK Health Security Agency, London, United Kingdom
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Ramsay
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
MBBS, FFPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie Lopez Bernal
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, United Kingdom
PhD, MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Jamie.LopezBernal2{at}ukhsa.gov.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Article usage

Article usage: September 2022 to August 2025

AbstractFullPdf
Sep 202235731231139
Oct 202237415323
Nov 202229311103
Dec 202214056116
Jan 2023881574
Feb 2023671348
Mar 2023931427
Apr 202347519
May 202340312
Jun 202336516
Jul 202334112
Aug 2023281211
Sep 202326625
Oct 202320218
Nov 20231828
Dec 20232408
Jan 20241606
Feb 202417013
Mar 202427419
Apr 20242567
May 20242123
Jun 202420611
Jul 202414318
Aug 202417823
Sep 202421520
Oct 20241257
Nov 20241037
Dec 20241328
Jan 202514611
Feb 202512631
Mar 2025421723
Apr 202520311
May 202521517
Jun 2025391515
Jul 2025191220
Aug 2025224
Back to top
PreviousNext
Posted September 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA.4 and BA.5 in England
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA.4 and BA.5 in England
Freja C. M. Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2022.08.31.22279444; doi: https://doi.org/10.1101/2022.08.31.22279444
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA.4 and BA.5 in England
Freja C. M. Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2022.08.31.22279444; doi: https://doi.org/10.1101/2022.08.31.22279444

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)